WiSE (Wireless Stimulation of the Endocardium Technology) CRT System
EBR Systems, Inc. · Decision date Dec 15, 2025
What did the FDA decide?
FDA records P240028/S004 as a supplement to PMA P240028, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 15, 2025.
FDA approval order statement
to update manufacturing lot release testing requirements for M1000 and M2000 catheters.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 15, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240028/S004
- Regulatory pathway
- PMA supplement
- Applicant
- EBR Systems, Inc.
- Product code
- SEG
- Decision code
- OK30
- Decision date
- Dec 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Leadless Cardiac Resynchronization Therapy (CRT).
- Applicant
- EBR Systems, Inc.
- Product code
- SEG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240028/S002 · Related supplement
WiSE (Wireless Stimulation of the Endocardium Technology) CRT System
P240028/S003 · Related supplement
WiSE (Wireless Stimulation of the Endocardium Technology) CRT System
P240028/S004 received
Application receipt date recorded by FDA.
P240028/S004 · FDA decision
30-Day Notice
P240028/S006 · Related supplement
WiSE (Wireless Stimulation of the Endocardium Technology) CRT System
Timeline entries are records held by MedtechLedger for P240028. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240028
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| EBR Systems, Inc. | PMA supplement | Sep 3, 2025 | FDA | |
| EBR Systems, Inc. | PMA supplement | Oct 3, 2025 | FDA | |
| EBR Systems, Inc. | PMA supplement | Mar 27, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
EBR Systems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 480 Oakmead Pkwy., Sunnyvale, CA, 94085
Sources and methodology
- Original FDA record: P240028/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

